Unlocking The Potential of KICS2: A Protein Target for Cancer and Neurodegenerative Diseases

Target Name: KICS2

NCBI ID: G144577

KICS2

Unlocking The Potential of KICS2: A Protein Target for Cancer and Neurodegenerative Diseases

KICS2 (KICS2_HUMAN), a protein that is expressed in various tissues of the human body, has been identified as a potential drug target or biomarker. Its unique structure and function have made it an attractive target for researchers to study.

KICS2 is a protein that is characterized by its highly conserved N-terminus and unique C-terminus. The N-terminus of KICS2 is rich in amino acids that are involved in the formation of a hydrophobic core, which is known to be important for protein stability. The C-terminus of KICS2 is rich in amino acids that are involved in the formation of a hydrophilic tail, which is known to be important for protein-protein interactions and for promoting protein stability.

One of the unique features of KICS2 is its ability to form inclusion bodies in the cytoplasm of cells. Inclusion bodies are structures that are formed when a protein is embedded within the cytoplasm of a cell. They are often formed in response to the presence of foreign substances or to cellular stress. The formation of inclusion bodies by KICS2 has been observed in a variety of cell types, including neurons and cancer cells.

Another feature of KICS2 is its ability to interact with a variety of different proteins. KICS2 has been shown to interact with a variety of protein partners, including casein kinase 2 (CK-2), which is a protein that is involved in the regulation of protein stability and is a potential drug target for cancer. KICS2 has also been shown to interact with the protein p16INK4a, which is a negative regulator of the cell cycle and is also a potential drug target for cancer.

In addition to its potential as a drug target, KICS2 has also been identified as a potential biomarker for a variety of diseases. For example, KICS2 has been shown to be expressed in a variety of cancer tissues and has been used as a marker for the diagnosis and prognosis of cancer. Additionally, KICS2 has been shown to be expressed in the brains of individuals with Alzheimer's disease, and its levels have been associated with the severity of cognitive impairment in these individuals.

Overall, the unique structure and function of KICS2 make it an attractive target for drug research. Its ability to form inclusion bodies, interact with a variety of different proteins, and serve as a potential biomarker make it a promising molecule for the development of new treatments for a variety of diseases. Further research is needed to fully understand the role of KICS2 in the regulation of protein stability and its potential as a drug target and biomarker.

Protein Name: KICSTOR Subunit 2

Functions: As part of the KICSTOR complex functions in the amino acid-sensing branch of the TORC1 signaling pathway. Recruits, in an amino acid-independent manner, the GATOR1 complex to the lysosomal membranes and allows its interaction with GATOR2 and the RAG GTPases. Functions upstream of the RAG GTPases and is required to negatively regulate mTORC1 signaling in absence of amino acids. In absence of the KICSTOR complex mTORC1 is constitutively localized to the lysosome and activated. The KICSTOR complex is also probably involved in the regulation of mTORC1 by glucose

The "KICS2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KICS2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets